Steven Erpelinck BSc. MBA
- AMS transporters
- PBPK modeling
We focus on ten societal areas.
TNO cooperates with companies, the public sector and other organisations, to apply our knowledge and expertise with and for others.
We develop knowledge not for its own sake, but for practical application.
TNO offers you the chance to do groundbreaking work and help customers and society with innovative, practical and smart solutions.
On TNO Insights you can read in-depth interviews and articles. Get inspired by TNO’s innovations!
Pharma companies want it. Regulators want it. Patients certainly want it: faster, more accurate, less expensive drug development. But with all the complexity that drug development entails, how can we accelerate the process? By eliminating some of the bottlenecks that delay the critical path. TNO has developed a range of tools, technology and data that enables pharma companies to achieve their objectives more swiftly and successfully than ever before.
Successful drug development is a lengthy, expensive and complicated process. What makes TNO the ideal partner to accelerate preclinical and clinical research? Our understanding of those complexities and our technologies, which address them.
At TNO, we innovate for the benefit of the pharmaceutical and biotech industry, for society and for patients. Our preclinical models and clinical platforms have proven value, and help drug companies reach key phases more swiftly and confidently.
In preclinical development stages, project leads are under pressure to identify novel targets and candidate compounds. To obtain meaningful results, early in vitro and in vivo studies should employ robust models that recapitulate critical human disease processes. TNO’s proven platforms boost preclinical research and offer insight into the efficacy, pharmacokinetics and safety of candidate compounds. We combine robust biological models with high-end analytics for specific and sensitive readouts.
Our extensive tissue biobank and database enables us to make head-to-head comparisons of preclinical testing results with pathways in human tissue or specific cells. This ensures a higher rate of translatability between early preclinical studies and later human ones.
In complex diseases where multiple organs are affected, understanding the pathways of disease onset and progression is key. This helps define key targets and the optimal therapeutic window, and drives more effective interventions. Time course studies that combine multiple (-omics) technologies in TNO’s translational animal models have been used to identify and validate several types of biomarkers, which improve early patient diagnosis of patients, efficacy testing of candidate drugs and patient stratification.
Our knowledge of disease mechanisms has enabled us to identify the molecular signatures of NASH-induced fibrosis in the circulation. These signatures are being validated in patient cohorts and might replace biopsies in the future. We have also uncovered molecular links between NASH and atherosclerosis development, enabling interventions that focus on the mechanisms of both diseases. We now aim to use a similar approach to gain better understanding of the processes involved in diabetic disease, and we are eager to work with partners to further increase knowledge of complex metabolic diseases.
Safety Package investigations usually begin with extensive animal testing to identify key metabolites that may affect drug safety or efficacy. But animals often develop different metabolites than humans do. TNO can offer smart technologies that identify relevant human metabolites already in Phase 1. This enables targeted safety testing in animals and a stronger basis for research that completes the safety package sooner and at a lower cost.
Secondly, classical tracing studies use high doses of radiation, which raises medical ethical questions and limits their usage to late-stage clinical trials. TNO’s unique combination of microtracing (100-1000x lower radiation levels) and AMS technology enable these metabolite studies to occur in the earliest stages of clinical study. This is not only safer for patients, but also provides more accurate information, earlier in the process. Microtracing also eliminates the need for high-dose radiation studies.
Ready to accelerate and de-risk your drug development process? Contact Steven Erpelinck or Robert Ostendorf.